Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 19

PMID 38893150

Authors

Alaa A A Aljabali

Mohammad A Obeid

Omar Gammoh

Mohamed El-Tanani

Vijay Mishra

Yachana Mishra

Sumedha Kapre

Sushesh Srivatsa Palakurthi

Sk Sarif Hassan

Debaleena Nawn

Kenneth Lundstrom

Altijana Hromic-Jahjefendic

Angel Serrano-Aroca

Elrashdy M Redwan

Vladimir N Uversky

Murtaza M Tambuwala

Affiliations

Soon will be listed here.

Abstract

Immunotherapy is a rapidly advancing field of research in the treatment of conditions such as cancer and autoimmunity. Nanomaterials can be designed for immune system manipulation, with precise targeted delivery and improved immunomodulatory efficacy. Here, we elaborate on various strategies using nanomaterials, including liposomes, polymers, and inorganic NPs, and discuss their detailed design intricacies, mechanisms, and applications, including the current regulatory issues. This type of nanomaterial design for targeting specific immune cells or tissues and controlling release kinetics could push current technological frontiers and provide new and innovative solutions for immune-related disorders and diseases without off-target effects. These materials enable targeted interactions with immune cells, thereby enhancing the effectiveness of checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Moreover, they allow for fine-tuning of immune responses while minimizing side effects. At the intersection of nanotechnology and immunology, nanomaterial-based platforms have immense potential to revolutionize patient-centered immunotherapy and reshape disease management. By prioritizing safety, customization, and compliance with regulatory standards, these systems can make significant contributions to precision medicine, thereby significantly impacting the healthcare landscape.

References

Zheng C, Wang Q, Wang Y, Zhao X, Gao K, Liu Q . In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice. Adv Mater. 2019; 31(32):e1902542. DOI: 10.1002/adma.201902542. View

Sujka M, Pankiewicz U, Kowalski R, Nowosad K, Noszczyk-Nowak A . Porous starch and its application in drug delivery systems. Polim Med. 2019; 48(1):25-29. DOI: 10.17219/pim/99799. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Mohammapdour R, Ghandehari H . Mechanisms of immune response to inorganic nanoparticles and their degradation products. Adv Drug Deliv Rev. 2021; 180:114022. PMC: 8898339. DOI: 10.1016/j.addr.2021.114022. View

Dash A, Cudworth 2nd G . Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1999; 40(1):1-12. DOI: 10.1016/s1056-8719(98)00027-6. View

Reddy N, Hernandez-Ilizaliturri F, Deeb G, Roth M, Vaughn M, Knight J . Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2007; 140(1):36-45. DOI: 10.1111/j.1365-2141.2007.06841.x. View

Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C . Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023; 8(1):450. PMC: 10716479. DOI: 10.1038/s41392-023-01674-3. View

Chao Y, Karmali P, Mukthavaram R, Kesari S, Kouznetsova V, Tsigelny I . Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. ACS Nano. 2013; 7(5):4289-98. DOI: 10.1021/nn400769e. View

Strzelec M, Detka J, Mieszczak P, Sobocinska M, Majka M . Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 2023; 14:1127704. PMC: 10033545. DOI: 10.3389/fimmu.2023.1127704. View

10.

Zhu Y, Tang K, Lv J . Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci. 2021; 42(10):857-869. DOI: 10.1016/j.tips.2021.07.001. View

11.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

12.

Gaur M, Misra C, Yadav A, Swaroop S, O Maolmhuaidh F, Bechelany M . Biomedical Applications of Carbon Nanomaterials: Fullerenes, Quantum Dots, Nanotubes, Nanofibers, and Graphene. Materials (Basel). 2021; 14(20). PMC: 8538389. DOI: 10.3390/ma14205978. View

13.

Yang K, Zhang C, Wang W, Wang P, Zhou J, Liang X . pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol Med. 2014; 11(1):34-43. PMC: 3969802. DOI: 10.7497/j.issn.2095-3941.2014.01.003. View

14.

Konkel J, Zhang D, Zanvit P, Chia C, Zangarle-Murray T, Jin W . Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. Immunity. 2017; 46(4):660-674. DOI: 10.1016/j.immuni.2017.03.015. View

15.

Cai D, Gao W, Li Z, Zhang Y, Xiao L, Xiao Y . Current Development of Nano-Drug Delivery to Target Macrophages. Biomedicines. 2022; 10(5). PMC: 9139084. DOI: 10.3390/biomedicines10051203. View

16.

. Immune discovery aplenty at twenty. Nat Rev Immunol. 2021; 21(10):613. DOI: 10.1038/s41577-021-00623-x. View

17.

Panigrahy D, Gilligan M, Huang S, Gartung A, Cortes-Puch I, Sime P . Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?. Cancer Metastasis Rev. 2020; 39(2):337-340. PMC: 7207990. DOI: 10.1007/s10555-020-09889-4. View

18.

Cazzamalli S, Dal Corso A, Neri D . Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments. Chimia (Aarau). 2017; 71(10):712-715. PMC: 5844459. DOI: 10.2533/chimia.2017.712. View

19.

Ohradanova-Repic A, Nogueira E, Hartl I, Gomes A, Preto A, Steinhuber E . Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells. Nanomedicine. 2017; 14(1):123-130. DOI: 10.1016/j.nano.2017.09.003. View

20.

Klasener K, Jellusova J, Andrieux G, Salzer U, Bohler C, Steiner S . CD20 as a gatekeeper of the resting state of human B cells. Proc Natl Acad Sci U S A. 2021; 118(7). PMC: 7896350. DOI: 10.1073/pnas.2021342118. View